Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sirnaomics Starts US Trial of siRNA Therapy for Squamous Cell Skin Cancer

publication date: Aug 22, 2022

Sirnaomics, a Suzhou-Maryland RNA company, has dosed the first patient in a US Phase I/II trial of its leading siRNA (small interfering RNA) candidate in patients with facial squamous cell skin cancer in situ. STP705 is already being tested in six other Phase II trials for various cancers. The 30/60/90μg dose escalation study will evaluate the safety, tolerability and efficacy of STP705 administered by intralesional injection. STP705 is a siRNA product designed to knock down both TGF-β1 and COX2 gene expression and is administered via a polypeptide nanoparticle (PNP)-enhanced delivery. More details....

Stock Symbol: (HK: 2257)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital